Very Delayed Acute Hepatitis after Pembrolizumab Therapy for Advanced Malignancy: How Long Should We Watch?

Immune checkpoint inhibitors (ICIs) have led to major therapeutic advances in the management of malignancy. Despite promising outcomes for some cancers, ICIs are linked to unique side-effects known as immune-related adverse events (IrAEs). These may affect a wide array of organ systems. In particula...

Descripción completa

Detalles Bibliográficos
Autores principales: Phan, Timothy, Patwala, Kurvi, Lipton, Lara, Knight, Virginia, Aga, Ahmad, Pianko, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985792/
https://www.ncbi.nlm.nih.gov/pubmed/33617506
http://dx.doi.org/10.3390/curroncol28010088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985792/
https://www.ncbi.nlm.nih.gov/pubmed/33617506
http://dx.doi.org/10.3390/curroncol28010088

Ejemplares similares